In this issue:
Appendectomy not associated with milder UC course
IL-23p19 antagonists vs. ustekinumab for CD
Impact of prior biologic exposure on ozanimod efficacy and safety
IBD, periconceptional disease activity and major congenital anomaly risk
Periodontitis and IBD incidence
Inadequate biologic efficacy for proximal ileal lesions in CD
Advanced dual-targeted therapy in refractory perianal CD
Anti-TNF from CD diagnosis is cost effective
Subcutaneous vedolizumab dose intensification in IBD
Vedolizumab faecal loss in UC
Please login below to download this issue (PDF)